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Purpose: Clinically important deterioration (CID) in chronic obstructive pulmonary disease
(COPD) is a novel composite endpoint that assesses disease stability. The association
between short-term CID and future economic and quality of life (QoL) outcomes has not
been previously assessed. This analysis considers 3-year data from the TOwards
a Revolution in COPD Health (TORCH) study, to examine this question.
Patients and methods: This post hoc analysis of TORCH (NCT00268216) compared
costs and utilities at 3 years among patients without CID (CID-) and with CID (CID+) at
24 weeks. A positive CID status was deﬁned as either: a deterioration in forced expiratory
volume in 1 second (FEV1) of ≥100 mL from baseline; or a ≥4-unit increase from baseline in
St George’s Respiratory Questionnaire (SGRQ) total score; or the incidence of a moderate/
severe exacerbation. Patients from all treatment arms were included. Utility change was
based on the EQ-5D utility index. Costs were based on healthcare resource utilization from
24 weeks to end of follow-up combined with unit costs for the UK (2016 GBP), and reported
as per patient per year (PPPY). Adjusted estimates were generated controlling for baseline
characteristics, treatment assignment, and number of CID criteria met.
Results: Overall, 3,769 patients completed the study and were included in the analysis
(stable CID- patients, n=1,832; unstable CID+ patients, n=1,937). At the end of follow-up,
CID- patients had higher mean (95% conﬁdence interval [CI]) utility scores than CID+
patients (0.752 [0.738, 0.765] vs 0.697 [0.685, 0.71]; difference +0.054; P<0.001), and lower
costs PPPY (£538 vs £916; difference: £378 [95% CI: £244, £521]; P<0.001). The cost
differential was primarily driven by the difference in general hospital ward days (P=0.003).
Conclusion: This study demonstrated that achieving early stability in COPD by preventing
short-term CID is associated with better preservation of future QoL alongside reduced
healthcare service costs.
Keywords: direct medical costs, EQ-5D, resource utilization, utilities
Plain language summary
Chronic obstructive pulmonary disease (COPD) is a complex and heterogeneous disease.
Consequently, it would be helpful to evaluate disease stability and potential progression using
outcomes that reﬂect this. Recently, clinically important deterioration (CID) was developed as an
endpoint to capture important short-term changes in key clinical features (lung function, health
status, and exacerbations), which indicate worsening of disease or disease instability. Studies have
shown that early CID (assessed up to 26 weeks) can predict adverse long-term clinical outcomes.
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However, the impact of early CID on a patient’s future quality of life,
healthcare service use and associated costs, is unknown. Data from
the 3-year TOwards a Revolution in COPDHealth (TORCH) clinical
trial in moderate-to-very-severe COPD was examined in patients
with early stability (CID- patients) or early instability (CID+ patients)
during 6 months of treatment. In the current analysis, we compared
the outcomes between CID- and CID+ patients in terms of subse-
quent annual costs, use of healthcare services and quality of life from
the time their short-termCID statuswas conﬁrmed until the end of the
study (up to 2.5 years). Compared with CID+ patients, stable CID-
patients had a better future quality of life and had lower future annual
costs mainly due to lower hospital admission costs. These results
suggest that achieving early disease stability in COPD might lead to
better quality of life and healthcare cost savings in the long term.
Introduction
Chronic obstructive pulmonary disease (COPD) is
a complex and heterogenous disease, characterized by
persistent respiratory symptoms, speciﬁcally airway
obstruction.1 COPD is a major cause of chronic morbidity
and mortality worldwide,2–4 and is associated with
a signiﬁcant economic burden.2,5 In the European Union,
COPD accounts for 56% (€38.6 billion) of the total cost of
respiratory disease.2 In the United States, the estimated
direct costs of COPD are $32 billion and indirect costs
were estimated at $20.4 billion in 2010.2,6
Comprehensive assessment of COPD symptoms is
recommended, including determination of the extent of
airﬂow limitation, the impact of airﬂow limitation/dyspnea
on the patient’s health status, and the risk of future events,
thus allowing treatment to be individualized based on
symptom severity and exacerbation risk.2,7 Developing
a reliable method by which the potential for COPD pro-
gression in individuals could be routinely monitored, simi-
lar to identifying poor control in asthma patients,8,9 is
a key objective on the pathway towards personalizing
current clinical care.10 It will enable healthcare profes-
sionals to identify high-risk patients earlier, as well as
identify the variety of factors that can best predict COPD
outcomes. Given the complexity and heterogeneity of
COPD, it is important that the method of measurement
be multidimensional, to assemble a comprehensive picture
of the potential for COPD progression.11,12
A novel composite endpoint assessing three dimen-
sions of clinically important deterioration (CID) in
COPD has been developed to assess and quantify
individual levels of disease deterioration on treatment,
and has been utilized to compare the effects of various
therapies on maintaining short-term COPD stability.13 The
CID endpoint has been used to demonstrate improved
disease stability with dual ﬁxed-dose long-acting muscari-
nic antagonist (LAMA)/long-acting β2-agonist (LABA)
combination therapies compared with placebo, inhaled
corticosteroid (ICS)/LABA dual therapy and LAMA or
LABA monotherapies,13–17 and with triple therapy (ICS/
LAMA/LABA in single or multiple inhaler[s]) compared
with ICS/LABA18,19 and placebo added to ICS/LABA.20
While the clinical aspects of CID have been
extensively studied, the economic and quality of life
(QoL) impact of avoiding CID remains unclear. This
study is the ﬁrst to consider the costs and utilities asso-
ciated with CID, in order to investigate if prevention of
short-term instability may be associated with preservation
of future QoL and reduced healthcare service costs, with
consequent beneﬁts to patients and payers.
Materials and methods
Objectives
The objective of this post hoc analysis of data prospectively
collected over 3 years was to compare the long-term economic
outcomes and utility consequences of COPD by patient CID
status at Week 24, using data from the TOwards a Revolution
in COPD Health (TORCH) study.21,22
Design and key results of the TORCH
study
The TORCH study (NCT00268216)21,22 was a 3-year,
multicenter, placebo-controlled, double-blind, randomized
parallel group study conducted in 42 countries to examine
the impact of COPD treatment on all-cause mortality.
Study design and outcomes have been previously
reported.21,22 In brief, after a 2-week run-in period,
patients were randomized to one of four different treat-
ment arms: ﬂuticasone propionate (FP) 500 mcg; salme-
terol (SAL) 50 mcg; FP/SAL 500/50 mcg; or placebo for
3 years. All-cause mortality rates were highest in the FP
500 mcg group (16.0%) and lowest in the FP/SAL
500/50 mcg group (12.6%). However, no signiﬁcant
reduction in all-cause mortality was observed with combi-
nation therapy, or either monotherapy, versus placebo.22
Secondary endpoints included QoL, assessed by total St
George’s Respiratory Questionnaire (SGRQ) and Euro
quality-of-life (EuroQoL) scores, lung function (assessed
as the mean change in pre- and post-bronchodilator forced
expiratory volume in 1 second [FEV1] from baseline to
Paly et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
International Journal of Chronic Obstructive Pulmonary Disease 2019:14940
3 years), and the frequency of moderate and severe
exacerbations.
Study design
Population
Eligible patients for the TORCH trial were ≥40 years of
age, with a diagnosis of COPD,23 current or former
smokers (≥10-pack-year history), with a pre-
bronchodilator FEV1<60% of the predicted value, <10%
reversibility in predicted FEV1, and a ratio of pre-
bronchodilator FEV1 to forced vital capacity of ≤70%.
In this post hoc analysis, patients from the TORCH study
population were included if they had complete available
data to allow for determination of CID status on treat-
ment at Week 24. This required at least one clinic visit
after starting treatment, in which a lung function test and
SGRQ were administered. A complete case analysis was
conducted for all patients who did not withdraw from the
study; therefore, patients were excluded from the analysis
if they withdrew from the TORCH study at any time, or if
they had incomplete data.
CID status was evaluated based on data collected until
a maximum of 182 days (expected Week 24 visit
+2 weeks) on randomized treatment, and was determined
based on the absence (CID-) or presence (CID+) of at least
one of the following three criteria denoting instability at or
before Week 24: FEV1 ≥100 mL decline from baseline; or
SGRQ total score ≥4-unit increase from baseline; or
a moderate or severe exacerbation. Long-term economic
outcomes and utility consequences were reported after
3 years of follow-up (Figure 1). No minimum or maximum
window for the end of follow-up (Week 156 visit) was
applied for patients who completed the study.
Baseline variables used within this analysis were age,
sex, body mass index (BMI), race, region, smoking status,
number of pre-treatment COPD medications, number of
prior exacerbations, modiﬁed Medical Research Council
(mMRC) dyspnea score, FEV1, SGRQ, and EuroQol
5-dimensional scale (EQ-5D) utility index.
Outcomes
All outcomes were presented by short-term CID status (stable
CID- or unstable CID+ patient subgroups) and stratiﬁed by the
treatments investigated within the TORCH study.22
Resource utilization
Patient resource utilization was assessed from Week 24 to
the end of follow-up and included: hospitalizations (num-
ber of general ward days and number of intensive care unit
[ICU] days), the number of emergency department (ED)
visits, the number of ofﬁce visits, the number of home
visits, and the number of outpatient visits.
Costs
All costs were based on 2016 Great British Pounds (GBP) and
total direct medical costs were estimated based on reported
healthcare resource utilization with unit costs applied for the
United Kingdom (Table S1). Unit costs were sourced from the
National Health Service (NHS) reference costs 2015–2016,24
or the Personal Social Service Research Unit.25
Utilities
Utility values were estimated from the EQ-5D health index
using the recommended tariffs derived from a UK popula-
tion survey.26 Utility change based on EQ-5D utility index
was calculated from baseline to the end of follow-up, and
from Week 24 to the end of follow-up. EQ-5D utility index
data were only collected in 21 of the 42 participating
countries for which validated translations of the instrument
were available, so analyses of utility were restricted to
study patients from those countries.
Statistical analyses
Multivariable adjustment was performed for all endpoints to
account for possible selection bias due to only including
CID assessment period
Randomization Determination of CID
status (CID-/CID+) at
Week 24 (Visit 4)
Assessment of clinical and
economic outcomes
24 weeks
Follow-up period
Up to 2.5 years
Figure 1 Study design.
Abbreviation: CID, clinically important deterioration.
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patients who did not withdraw and for differences in patient
characteristics given that categorization occurred post
randomization. Adjusted analyses were conducted using the
following covariates: age, sex, BMI, race, region, smoking
status at baseline, number of prior COPD treatments, number
of prior exacerbations, mMRC at baseline, FEV1 at baseline,
CID status, treatment, CID status*CID type, and CID status*-
treatment. CID type was deﬁned by the type (FEV1, SGRQ, or
exacerbation CID) and number of CID criteria met by the
patient. Baseline EQ-5D was also included as a covariate in
the analyses of utilities. Linear regression was conducted for
the utility outcomes. For resource use counts, generalized
linear models with a negative binomial distribution were
used. Missing data were assumed to most likely be due to
withdrawal from the study. As data from patients who with-
drew from the study were likely to be informative, inverse
probability-weighting (IPW) was applied for all adjusted
analyses.
Cost estimates were generated using a two-part model-
ing approach to properly account for patients with either
zero observed costs or outlier costs from the top 3 costing
patients. The two-part model was conducted as follows:
part 1: run logistic regression to predict probability of
having positive costs (P[Y>0], where Y=costs); part 2:
run generalized linear model with a gamma distribution
and log link among patients with positive costs (Y>0),
then predict costs for the whole sample (E [Y|Y>0]).
Adjusted mean cost estimates for each patient were calcu-
lated using the following equation: P(Y>0)*(E [Y|Y>0]);
95% conﬁdence intervals (CI) were generated via 5,000
bootstrapped samples (sampling with replacement).
Results
Study population
In total, 8,554 patients were enrolled in the TORCH study,
6,184 (72.3%) were randomized and 6,112 (71.5%) were
included in the efﬁcacy population.22 Of the randomized
patients, 3,769 patients completed the study and had data
available at Week 24 for determination of CID status and
thus were included in the post hoc analysis (stable CID-
subgroup: N=1,832; unstable CID+ subgroup: N=1,937)
(Figure 2). A summary of patient demographics and base-
line characteristics is provided in Table 1.
Resource utilization
From Week 24 to the end of follow-up, the stable CID- sub-
group had signiﬁcantly lower mean (95% CI) resource use per
patient per year (PPPY) across a number of endpoints com-
pared with the unstable CID+ subgroup, including the number
of general ward days (mean difference −0.410; P=0.003),
ofﬁce visits (mean difference −0.191; P<0.001), home visits
(mean difference−0.008;P<0.001) and outpatient visits (mean
difference −0.067; P=0.029) (Table S2). Resource use by CID
status and by treatment is presented in Table 2.
Costs
The total mean (95% CI) costs PPPY in the stable CID-
subgroup were signiﬁcantly lower than those in the
unstable CID+ subgroup (£538 [458, 628] vs £916 [806,
1,050]; P<0.001) (Figure 3A). Similar results were seen
when costs were analyzed by randomized treatment type,
with the exception of SAL 50 mcg (Figure 3B).
Utilities
EQ-5D utilities were signiﬁcantly higher in the stable
CID- subgroup compared with the unstable CID+ sub-
group at Week 24 (mean difference +0.043; P<0.001),
and at end of the 3-year follow-up period (mean difference
+0.054; P<0.001) (Figure 4). The mean (95% CI) change
from baseline at 3 years was 0.005 (−0.009, 0.019) for the
CID- subgroup and −0.049 (−0.061, −0.036) in the CID+
subgroup (difference: +0.054; P<0.001) (Table S2). There
was no signiﬁcant difference between the CID- and CID+
subgroups in change in utility from Week 24 to the end of
follow-up (Figure 4/Table S2).
When analyzed by treatment, the difference in EQ-5D
utility at the end of the 3-year follow-up between CID- and
CID+ subgroups was statistically signiﬁcant in all treatment
groups (Table 3). Similar results were observed for the differ-
ence between CID status subgroups in EQ-5D utility change
from baseline to end of follow-up in each treatment group
(Table 3). The mean difference between CID subgroups was
lowestwithin the FP500mcg treatment group, as a result of the
lower utility scores within the stable CID- subgroup for this
treatment (Table 3).22 Utilities at Week 24 were higher in the
CID- versus theCID+ subgroup for all treatments, although the
difference was not statistically signiﬁcant for FP 500 mcg
(Table 3). There was no signiﬁcant difference between the
CID- and CID+ subgroup in change in utility from Week 24
to end of follow-up in any of the treatment groups (Table 3).
Discussion
The results of this analysis suggested that overall, patients who
were more stable (CID-) at the 6-month time point (Week 24)
in the TORCH study had signiﬁcantly better economic and
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QoL outcomes throughout the remaining period of assessment
compared with those patients with a short-term CID (CID+).
Patients with early CID events showed signiﬁcantly lower EQ-
5D utilities compared with more stable patients who remained
free of CID events at 24 weeks. Early loss in utility established
atWeek 24was still apparent at the end of the 3-year follow-up,
highlighting that early loss in health statuswas not recovered in
the follow-up period andmay continue to be compoundedwith
additional events. In addition, while these results demonstrated
that CID- patients had signiﬁcantly higher EQ-5D utilities
compared with CID+ patients, the utility scores from
24 weeks to 3 years were generally stable with marginal
subsequent changes, indicating that the key impact of CID
was seen early in the study. Furthermore, the loss in EQ-5D
in the CID+ subgroup was largely consistent across all treat-
ment groups fromWeek 24 to the end of follow-up, indicating
that CID status could be used as a measure of short-term
responsiveness to treatment that may have long-term predic-
tive value.
A study by Nolan et al suggested that change of >0.050
in EQ-5D utility can be considered clinically relevant.27 In
the analysis presented here, the mean difference between
the CID- and CID+ subgroups in EQ-5D utility change
from baseline to the end of the 3-year follow-up period
was +0.054, which suggests that avoiding early CID may
be associated with higher EQ-5D utility scores and
improvements in the patient’s subsequent perception of
health. In terms of costs, the total mean costs PPPY in the
CID- and CID+ subgroups were £538 and £916, respec-
tively, resulting in a mean PPPY cost difference of £378
(41% lower costs for stable CID- patients). In comparison,
the cost of a moderate exacerbation according to the NHS
reference costs for 2010–2011, as used in a retrospective
cohort study by Punekar et al, was £85.28 When adjusted to
2016 GBP,29 this cost would be £83, indicating that the
observed annual cost saving PPPY associated with avoiding
an early CID would be over 4 times higher than that of
avoiding one moderate exacerbation.
In this analysis, resource use in the CID- subgroup was
signiﬁcantly lower than in the CID+ subgroup from Week
24 to the end of follow-up, across a number of endpoints,
including general ward days, ofﬁce visits, home visits, and
outpatient visits. The cost differential between the CID
status subgroups was largely driven by the difference in
TORCH efficacy population, N=6,112
Did not withdraw prior to 24 weeks 
and had data available to 
evaluate CID status at 24 weeks
n=5,292/6,112 (86.6%)
Completed the study
n=3,769/5,292 (71.2%)
Complete EQ-5D assessments
n=1,989/3,769 (52.8%)
Patients with CID- status at Week 24
n=2,421/5,292 (45.7%)
CID-
n=1,832/3,769 (48.6%)
CID-
n=929/1,989 (46.7%)
Patients with CID+ status at Week 24
n=2,871/5,292 (54.3%)
CID+
n=1,937/3,769 (51.4%)
CID+
n=1,060/1,989 (53.3%)
Figure 2 Patient disposition.
Abbreviations: CID, clinically important deterioration; COPD, chronic obstructive pulmonary disease; EQ-5D, EuroQol 5-dimensional scale; TORCH, TOwards
a Revolution in COPD Health.
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general ward days. This analysis suggests that achieving
disease stability by preventing short-term CID may be
associated with a reduction in costs generally related
with worsening COPD. Data from the World Health
Organization from 2008 indicated that the cost per bed
per day in the UK was slightly more expensive than
equivalent costs in Spain and Italy, but slightly cheaper
than equivalent costs in France, Germany, and the USA,
therefore placing the UK costs as somewhat of an
average.30 The results of this analysis and the identiﬁca-
tion of general ward days as the deﬁning cost driver for
CID+ patients, could therefore be broadly applicable to
other countries in Europe and to the USA. Costs by treat-
ment group were consistent with the overall CID analysis,
whereby all treatment groups demonstrated a statistically
signiﬁcant mean difference in favor of CID- patients, with
the exception of the SAL 50 mcg treatment arm, for which
the difference in annual costs per patient by CID status
was not signiﬁcant.
The correlation of short-term characterization of CID
status with long-term clinical outcomes has been previously
reported, using the combined data of TORCH22 and the
Table 1 Baseline demographics and characteristics
CID- (N=1,832) CID+ (N=1,937)
Age, mean (SD) 64.4 (8.4) 64.1 (8.2)
Male, n (%) 1,442 (79) 1,472 (76)
Ethnicity, n (%)
White 1,458 (80) 1,581 (82)
Asian 279 (15) 242 (12)
Black 29 (2) 22 (1)
American Hispanic 54 (3) 74 (4)
Other 12 (1) 18 (1)
Region, n (%)
Western Europe 537 (29) 640 (33)
USA 330 (18) 400 (21)
Eastern Europe 457 (25) 388 (20)
Asia Paciﬁc 276 (15) 240 (12)
Other 232 (13) 269 (14)
Current smoker, n (%) 803 (44) 856 (44)
Number of prior COPD treatments, mean (SD) 2.9 (1.5) 3.2 (1.6)
Patients who experienced an exacerbation in previous 12 months, n (%) 940 (51) 1,149 (59)
mMRC category, n (%)
0 140 (8) 164 (8)
1 904 (49) 812 (42)
2 544 (30) 656 (34)
3 204 (11) 242 (12)
4 40 (2) 60 (3)
FEV1 (mL), mean (SD) 1,269.3 (431.5) 1,292.3 (447.3)
SGRQ, mean (SD) 47.3 (16.5) 48.0 (17.4)
EQ-5D, mean (SD)* 0.755 (0.200) 0.736 (0.213)
CID type, n (%)
FEV1 criterion only NA 472 (24)
SGRQ criterion only NA 252 (13)
Exacerbation criterion only NA 692 (36)
Any 2 criteria NA 455 (23)
All 3 criteria NA 66 (3)
Note: *Baseline EQ-5D across all patients was used to generate adjusted estimates for all other EQ-5D outcomes.
Abbreviations: CID, clinically important deterioration; COPD, chronic obstructive pulmonary disease; EQ-5D, EuroQol 5-dimensional scale; FEV1, forced expiratory
volume in 1 second; mMRC, modiﬁed Medical Research Council; NA, not applicable; SD, standard deviation; SGRQ, St George’s Respiratory Questionnaire.
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Evaluation of COPD Longitudinally to Identify Predictive
Surrogate Endpoints (ECLIPSE; NCT00292552)31,32 stu-
dies, both of which evaluated patients over a 3-year
period.33 In both studies, CID+ patients had a clinically sig-
niﬁcant protracted deﬁcit in FEV1 and health status and
a higher risk of moderate or severe exacerbation (P<0.001
vs CID- subgroup), together with a higher all-cause mortality
risk (P<0.05 vs CID-).33 Similarly, a post hoc analysis of the
4-year Understanding Potential Long-Term Impacts on
Function with Tiotropium (UPLIFT; NCT00144339)34
study demonstrated that CID events at a 6-month interval
predicted future moderate and severe exacerbations, as well
as all-cause mortality.35 The increased hospitalization risk in
CID+ patients has therefore been demonstrated from
a clinical perspective and the results of this study suggest
that these clinical observations may be supported by their
corresponding long-term economic impact.
This study is the ﬁrst to consider the economic and
QoL outcomes associated with the emerging concept of
short-term CID. While previous publications have
demonstrated that short-term CID is associated with
poor clinical outcomes,33,35 an understanding of the
cost and utility implications of avoiding short-term
CID through better disease management further bolsters
the relevance of a monitoring tool to assess short-term
stability in COPD for healthcare professionals, patients
Table 2 Healthcare resource utilization by CID status and by treatment
CID- (N=2,421) CID+ (N=2,871) Mean difference
(CID- vs CID+)
P-value
General ward days PPPY, mean (95% CI)
Placebo 0.587 (0.389, 0.886) 1.475 (1.049, 2.076) −0.889 <0.001
FP 500 mcg 0.638 (0.438, 0.931) 1.154 (0.821, 1.622) −0.516 0.023
SAL 50 mcg 0.560 (0.386, 0.813) 0.694 (0.492, 0.977) −0.133 0.409
FP/SAL 500/50 mcg 0.645 (0.454, 0.915) 0.898 (0.631, 1.278) −0.253 0.191
ICU days PPPY, mean (95% CI)
Placebo 0.016 (0.003, 0.089) 0.076 (0.014, 0.412) −0.060 0.218
FP 500 mcg 0.029 (0.006, 0.136) 0.005 (0.001, 0.029) +0.024 0.166
SAL 50 mcg 0.010 (0.002, 0.057) 0.004 (0.001, 0.024) +0.006 0.454
FP/SAL 500/50 mcg 0.047 (0.010, 0.220) 0.030 (0.005, 0.179) +0.017 0.722
ED visits PPPY, mean (95% CI)
Placebo 0.017 (0.010, 0.028) 0.060 (0.042, 0.085) −0.043 <0.001
FP 500 mcg 0.015 (0.009, 0.025) 0.033 (0.022, 0.048) −0.018 0.015
SAL 50 mcg 0.028 (0.018, 0.043) 0.034 (0.023, 0.050) −0.006 0.520
FP/SAL 500/50 mcg 0.021 (0.014, 0.032) 0.048 (0.034, 0.069) −0.028 0.003
Ofﬁce visits PPPY, mean (95% CI)
Placebo 0.279 (0.220, 0.355) 0.479 (0.395, 0.580) −0.199 <0.001
FP 500 mcg 0.242 (0.193, 0.302) 0.605 (0.500, 0.732) −0.363 <0.001
SAL 50 mcg 0.253 (0.204, 0.314) 0.397 (0.326, 0.482) −0.144 0.003
FP/SAL 500/50 mcg 0.274 (0.223, 0.337) 0.363 (0.297, 0.444) −0.089 0.056
Home visits PPPY, mean (95% CI)
Placebo 0.003 (0.001, 0.008) 0.012 (0.005, 0.026) −0.009 0.027
FP 500 mcg 0.003 (0.001, 0.008) 0.014 (0.006, 0.029) −0.011 0.013
SAL 50 mcg 0.003 (0.001, 0.009) 0.009 (0.004, 0.021) −0.005 0.146
FP/SAL 500/50 mcg 0.005 (0.002, 0.013) 0.012 (0.006, 0.026) −0.006 0.159
Outpatient visits PPPY, mean (95% CI)
Placebo 0.154 (0.112, 0.212) 0.255 (0.197, 0.331) −0.101 0.016
FP 500 mcg 0.122 (0.090, 0.164) 0.269 (0.209, 0.347) −0.147 <0.001
SAL 50 mcg 0.240 (0.180, 0.320) 0.197 (0.150, 0.257) +0.043 0.324
FP/SAL 500/50 mcg 0.164 (0.125, 0.215) 0.213 (0.163, 0.278) −0.049 0.176
Abbreviations: CI, conﬁdence interval; CID, clinically important deterioration; ED, emergency department; FP, ﬂuticasone propionate; GBP, Great British Pounds; ICU,
intensive care unit; PPPY, per patient per year; SAL, salmeterol.
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and payers, in order to optimize therapy and reduce
irrecoverable costs. Furthermore, the analysis of utilities
within this study, and the signiﬁcant differences identi-
ﬁed in utilities between CID- and CID+ patient
subgroups, could be utilized within health technology
assessments and cost-effectiveness evaluations.
However, further studies are required to validate CID
as a potential surrogate endpoint for these longer-term
outcomes. The consideration of CID status by treatment
within this study also highlights the potential value of
applying this composite endpoint to the evaluation of
COPD treatments earlier in a treatment’s clinical
program to better demonstrate the combined clinical
and economic strengths of the treatment versus standard
of care therapies in COPD.
The results of this analysis demonstrate that stable
patients without short-term CID have reduced costs and
improved QoL in the long-term, compared with unstable
CID+ patients. There are three possible explanations for
this: 1. the stable CID- and unstable CID+ subgroups were
inherently different at baseline and as such had different
short- and long-term outcomes; 2. treatments that are
effective/ineffective in the short-term continue to be effec-
tive/ineffective in the long-term; 3. treatments that stabi-
lize COPD in the short-term prevent longer-term
irrecoverable deterioration. Based on the current clinical
1,600
1,400
1,200
1,000
800
600
400
200
0
Total direct costs PPPY (all treatments)
538
916
Mean difference £378
(95% CI: 244, 521)
P<0.001
CID-
CID+
C
os
ts
 (2
01
6 
G
B
P
)
–500 0 500 1,000 1,500
Mean difference in costs (2016 GBP); CID+ vs CID-
P<0.001
P<0.001
P<0.001
P=0.139
P=0.003
All treatments
Placebo
FP 500 mcg
SAL 50 mcg
FP/SAL 500/50 mcg
A
B
Figure 3 Total direct costs PPPY* (2016 GBP)† by CID status, for all treatments (A) and by individual treatment (B). *Cost data are presented to three signiﬁcant ﬁgures for
values of four ﬁgures or more and to the nearest pound for values of three ﬁgures or less; †adjusted using a two-part modeling approach, where a logistic regression was run
to predict the likelihood of having costs >0, followed by a generalized linear model (gamma distribution with a log link) run for patients with positive costs. The results of
these two models were then used to calculate predicted cost estimates for each patient. 95% CIs were generated using 5,000 bootstrapped samples (sampling with
replacement). Analysis of complete cases was weighted by the inverse probability of being a complete case.
Abbreviations: CI, conﬁdence interval; CID, clinically important deterioration; FP, ﬂuticasone propionate; GBP, Great British Pounds; PPPY, per patient per year; SAL,
salmeterol.
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evidence, we think that explanation 1 is unlikely. Our
multivariate analyses focused on the study survivor popu-
lation at 6 months and adjusted for baseline characteristics
of CID- and CID+ subgroups by treatment, CID type at
Week 24, and interaction between CID status at Week 24
and treatment. Moreover, the published CID analyses of
the TORCH and ECLIPSE studies, which focused on
clinical outcomes, demonstrated that the demographics
and baseline characteristics of CID- and CID+ patients
were generally similar.33 In addition, in the landmark
0.85
0.8
0.75
0.7
0.65
0.6
Baseline Week 24 3 years
Difference = +0.011, P=0.602
+0.054,
P<0.001
+0.043,
P<0.001
CID- (stable, n=929)*
CID+ (unstable, n=1,060)*
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Figure 4 EQ-5D score by time and CID status at Week 24 and 3 years. *EQ-5D was administered in only a subset of countries participating in the TORCH study.
Abbreviations: CID, clinically important deterioration; EQ-5D, EuroQol 5-dimensional scale; TORCH, TOwards a Revolution in COPD Health.
Table 3 EQ-5D utility changes by CID status and by treatment
EQ-5D, N* CID- (N=2,421) CID+ (N=2,871) Mean difference
(CID- vs CID+)
P-value
929 1,060
EQ-5D utility at 3 years, mean (95% CI)
Placebo 0.749 (0.720, 0.779) 0.685 (0.660, 0.711) +0.064 0.001
FP 500 mcg 0.740 (0.713, 0.768) 0.701 (0.676, 0.726) +0.039 0.038
SAL 50 mcg 0.750 (0.723, 0.778) 0.696 (0.671, 0.720) +0.055 0.006
FP/SAL 500/50 mcg 0.766 (0.739, 0.792) 0.706 (0.682, 0.731) +0.059 0.001
EQ-5D utility change from baseline to
3 years, mean (95% CI)
Placebo 0.003 (−0.027, 0.033) −0.061 (−0.086, −0.036) +0.064 0.001
FP 500 mcg −0.006 (−0.034, 0.021) −0.045 (−0.070, −0.020) +0.039 0.038
SAL 50 mcg 0.004 (−0.023, 0.031) −0.050 (−0.075, −0.026) +0.055 0.004
FP/SAL 500/50 mcg 0.019 (−0.007, 0.046) −0.040 (−0.065, −0.015) +0.059 0.001
EQ-5D utility atWeek 24,mean (95%CI)
Placebo 0.786 (0.762, 0.811) 0.736 (0.716, 0.757) +0.050 0.002
FP 500 mcg 0.762 (0.740, 0.785) 0.734 (0.714, 0.754) +0.028 0.069
SAL 50 mcg 0.786 (0.764; 0.808) 0.743 (0.723, 0.763) +0.043 0.007
FP/SAL 500/50 mcg 0.798 (0.777, 0.820) 0.748 (0.727, 0.768) +0.051 <0.001
EQ-5D utility change from Week 24 to
3 years, mean (95% CI)
Placebo −0.037 (−0.070, −0.004) −0.051 (−0.079, −0.023) +0.014 0.523
FP 500 mcg −0.022 (−0.052, 0.008) −0.033 (−0.060, −0.006) +0.011 0.600
SAL 50 mcg −0.036 (−0.066, −0.006) −0.047 (−0.074, −0.021) +0.012 0.567
FP/SAL 500/50 mcg −0.033 (−0.061, −0.004) −0.041 (−0.068, −0.014) +0.009 0.672
Note: *EQ-5D was administered in only a subset of countries participating in the TORCH study.
Abbreviations: CI, conﬁdence interval; CID, clinically important deterioration; ED, emergency department; EQ-5D, EuroQol 5-dimensional scale; FP, ﬂuticasone
propionate; GBP, Great British Pounds; ICU, intensive care unit; PPPY, per patient per year; SAL, salmeterol; SGRQ, St George’s Respiratory Questionnaire; TORCH,
TOwards a Revolution in COPD Health.
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COPD studies TORCH, ECLIPSE and UPLIFT, patients
who had a CID event (according to the same deﬁnition of
CID) in the ﬁrst 6–12 months of these studies were found
to have worse long-term outcomes, including increased
mortality.33,36 The ECLIPSE and UPLIFT studies allowed
for standard of care therapy to be adjusted over 3 or
4 years,31,34 and in the UPLIFT prognostic CID analysis,
adjusting for important baseline predictors of risk did not
diminish the power of the composite CID or any of its
individual components to detect consistent increased
mortality risk between CID+ and CID- patients.36
Therefore, together the evidence indicates that explana-
tions 2 or 3 or a combination of these are more likely, and
that short-term treatment failure assessed using CID is
linked to long-term treatment failure and potential sus-
tained disease progression. While it does not negate the
need for other baseline assessment of prognosis (eg,
comorbidities, exercise tolerance), the CID endpoint
could provide a framework for the monitoring of short-
term treatment failure advocated by the GOLD report,2
and could help identify patients with a high risk of dis-
ease progression and sustained poor long-term outcomes.
While this is the ﬁrst analysis to consider economic
and QoL outcomes of short-term CID status, the follow-up
analysis was limited to 3 years, which, due to the chronic
nature of COPD, may be perceived as insufﬁcient.
However, as this endpoint was associated with increased
hospital admission costs in the current analysis, and with
increased all-cause mortality in several other post hoc
analyses of long-term interventional studies,33,36 the
results from this study should nevertheless be strongly
considered and further validated. A multi-component sta-
bility assessment based on CID events in several disease
measures may also be considered less focused than mon-
itoring exacerbations alone. However, in a recent 3-year
follow up of the Danish National COPD Registry, higher
respiratory and all-cause mortality was observed in symp-
tomatic low exacerbation risk patients than in patients with
fewer symptoms and a high exacerbation risk.37 Thus, the
concept of disease stability measured across multiple dis-
ease dimensions may be important to identify future risk
beyond exacerbations.
A limitation of this analysis is that the TORCH study
assessed health status at 6-monthly intervals, therefore in
this study it was only possible to assess CID status at
Week 24. Patients who may have deteriorated at an earlier
or later time point were therefore not categorized as CID+,
thereby potentially reducing the observed cost and utility
difference between the CID status subgroups. Inclusion of
other more frequent timepoints for CID assessment would
likely shed further light on the true cost and utility differ-
ences between these subgroups.
Moreover, this analysis focused on unscheduled
resource use and costs, as collected per the TORCH pro-
tocol. Treatment-speciﬁc costs were not included because
patients were pooled across treatment arms to assess the
differences between the CID subgroups independent of
treatment. Additionally, regular monitoring costs were
not included as these would have been dictated by the
trial protocol rather than reﬂecting real-world practice.
Nevertheless, these are costs that should be considered to
more completely evaluate the economic impact of CID.
Analyses of economic and QoL outcomes were also
subject to the completeness of patient data available from
the TORCH study. IPW was applied to all complete cases
to account for patient withdrawals after the 6-month cut-
off. There may nevertheless be potential bias in the esti-
mation of the treatment-speciﬁc effects of the presence of
CID, due to the heterogeneity within the CID subgroups
across treatment arms. However, multivariate analysis was
used to adjust for baseline characteristics of CID- and
CID+ patient subgroups by treatment, CID type at the
Week 24 visit, and interaction between CID status at
Week 24 and treatment. Finally, as CID status allocation
was not a randomized decision, there may be additional
confounding variables that were not captured in the
TORCH study and could therefore not be adjusted for in
this speciﬁc analysis.
Conclusion
This study is the ﬁrst to consider the economic and QoL
outcomes associated with short-term CID. The results
demonstrate that the occurrence of short-term CID, in addi-
tion to having long-term clinical consequences, is associated
with sustained poorer QoL and higher health service costs.
The improvements in long-term QoL and economic out-
comes associated with early optimization of therapy to sta-
bilize COPD therefore confer beneﬁts from both the patient
and the payer perspective. Although short-term CID needs to
undergo further prospective validation, particularly in rela-
tion to whether later optimization of therapy prevents irre-
coverable deterioration (ie if treatment escalation after the
event can fully reverse the CID), it nevertheless appears to
be a useful endpoint to assess the beneﬁts of early optimal
therapy in future clinical trials in COPD.
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CI, conﬁdence interval; CID, clinically important dete-
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EuroQol, Euro quality-of-life; FEV1, forced expiratory
volume in 1 second; FP, ﬂuticasone propionate; FVC,
forced vital capacity; GBP, Great British Pounds; ICS,
inhaled corticosteroid; ICU, intensive care unit; IPW,
inverse probability-weighting; LABA, long-acting β2-
agonist; LAMA, long-acting muscarinic antagonist;
mMRC, modiﬁed Medical Research Council; NHS,
National Health Service; PPPY, per patient per year;
QoL, quality of life; SAL, salmeterol; SGRQ, St
George’s Respiratory Questionnaire; TORCH, TOwards a
Revolution in COPD Health.
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Table S1 Direct medical costs included in the CID analysis
Resource Unit cost
(2016 GBP)
Source/assumptions
General ward day 1,307.26 NHS reference cost 2015–16; adult critical care, 0–6 organs supported – code XC01Z-XC06Z
ICU day 425.81 NHS reference cost 2015–2016; weighted average costs by all COPD severities for nonelective
long stay
ED visit 195.81 NHS reference cost 2015–2016; VB05Z – emergency medicine, category 2 investigation with
category 3 treatment, type-1 non-admitted
Ofﬁce visit 65.86 Personal social service research unit – unit costs of health & social care 2015, clinical consultation
lasting 17.2 mins; inﬂated to 2016
Home visit 129.88 Personal social service research unit – unit costs of health & social care 2011, home visit lasting
23.4 mins; inﬂated to 2016
Outpatient visit 145.54 NHS reference cost 2015–2016; WF01A – respiratory medicine
Abbreviations: CID, clinically important deterioration; COPD, chronic obstructive pulmonary disease; ED, emergency department; GBP, Great British Pounds; ICU,
intensive care unit; NHS, national health service.
Table S2 EQ-5D utility changes and health resource utilization by CID status
EQ-5D, N* CID- CID+ Mean difference
(CID- vs CID+)
P-value
929 1,060
EQ-5D utility at baseline† 0.756 (0.737, 0.755)
EQ-5D utility at 3 years, mean (95% CI) 0.752 (0.738, 0.765) 0.697 (0.685, 0.710) +0.054 <0.001
EQ-5D utility change from baseline to 3 years, mean
(95% CI)
0.005 (−0.009, 0.019) −0.049 (−0.061, −0.036) +0.054 <0.001
EQ-5D utility at Week 24, mean (95% CI) 0.783 (0.772, 0.795) 0.741 (0.730, 0.751) +0.043 <0.001
EQ-5D utility change from Week 24 to 3 years, mean
(95% CI)
−0.032 (−0.047, −0.017) −0.043 (−0.057, −0.029) +0.011 0.602
Healthcare resource utilization, N 1,832 1,937
General ward days PPPY, mean (95% CI) 0.607 (0.502, 0.733) 1.017 (0.859, 1.205) −0.410 0.003
ICU days PPPY, mean (95% CI) 0.022 (0.010, 0.050) 0.015 (0.007, 0.033) +0.007 0.594
ED visits PPPY, mean (95% CI) 0.020 (0.015, 0.025) 0.042 (0.035, 0.052) −0.023 <0.001
Ofﬁce visits PPPY, mean (95% CI) 0.261 (0.234, 0.292) 0.452 (0.410, 0.499) −0.191 <0.001
Home visits PPPY, mean (95% CI) 0.003 (0.002, 0.006) 0.012 (0.007, 0.018) −0.008 <0.001
Outpatient visits PPPY, mean (95% CI) 0.165 (0.143, 0.192) 0.233 (0.204, 0.265) −0.067 0.029
Notes: *EQ-5D was evaluated in only a subset of countries participating in the TORCH study; †baseline EQ-5D across all patients was used to generate adjusted estimates
for all other EQ-5D outcomes.
Abbreviations: CI, conﬁdence interval; CID, clinically important deterioration; ED, emergency department; EQ-5D EuroQol 5-dimensional scale; FP, ﬂuticasone
propionate; GBP, Great British Pounds; ICU, intensive care unit; PPPY, per patient per year; SAL, salmeterol; SGRQ, St George’s Respiratory Questionnaire; TORCH,
TOwards a Revolution in COPD Health.
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